Cargando…
KRAS oncogene may be another target conquered in non‐small cell lung cancer (NSCLC)
Kirsten rat sarcoma viral oncogene homolog (KRAS) is one of the most common mutant oncogenes in non‐small cell lung cancer (NSCLC). The survival of patients with KRAS mutations may be much lower than patients without KRAS mutations. However, due to the complex structure and diverse biological proper...
Autores principales: | Chen, Hanxiao, Zhao, Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7705909/ https://www.ncbi.nlm.nih.gov/pubmed/33022831 http://dx.doi.org/10.1111/1759-7714.13538 |
Ejemplares similares
-
Conquering oncogenic KRAS and its bypass mechanisms
por: Hou, Pingping, et al.
Publicado: (2022) -
Targeting Oncogenic KRAS in Non-Small-Cell Lung Cancer
por: Sunaga, Noriaki, et al.
Publicado: (2021) -
Targeting the PI3K/Akt/mTOR pathway in non‐small cell lung cancer (NSCLC)
por: Tan, Aaron C.
Publicado: (2020) -
The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC)
por: Salgia, Ravi, et al.
Publicado: (2021) -
Oncogene addiction and tumor mutational burden in non‐small‐cell lung cancer: Clinical significance and limitations
por: Smolle, Elisabeth, et al.
Publicado: (2019)